Humanized Cd7 Car-T Cells
T-Cell Non-Hodgkin Lymphoma
Explore 84 assets in T-Cell Non-Hodgkin Lymphoma →Floatz Rating
CCC53/100
Confidence
Indicative
Sponsor
The First Affiliated Hospital of Soochow University
Modality
Cell therapy
Development Phase
Phase 2
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
38Moderate confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT05059912CT.gov CD7 CAR T-cell for R/R CD7+ T Cell Lymphoma | — | Unknown | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · T-Cell Non-Hodgkin Lymphoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Humanized Cd7 Car-T Cells (this asset) | The First Affiliated Hospital of Soochow University | P2 | CCC · 53 |
| Fludarabine | GC Cell Corporation | P2 | BBB |
| Brentuximab Vedotin | Yale University | P4 | BBB |
| Cyclophosphamide | GC Cell Corporation | P3 | BB |
| Rituximab | Memorial Sloan Kettering Cancer Center | P2 | BB |
| Lenalidomide | Samsung Medical Center | P2 | BB |
| Tacrolimus | M.D. Anderson Cancer Center | P2 | BB |
| Melphalan | Sichuan University | P3 | BB |
| Busulfanum | Sichuan University | P3 | BB |
+42 more in the T-Cell Non-Hodgkin Lymphoma cohort
Other indications for Humanized Cd7 Car-T Cells
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| T Lymphoblastic Leukemia/Lymphoma | — | P1/2 | CC · 47 |
| Mixed Phenotype Acute Leukemia | — | P1/2 | CC · 43 |
| Acute Myeloid Leukemia | — | P1/2 | CC · 40 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Humanized Cd7 Car-T Cells in T-Cell Non-Hodgkin Lymphoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/humanized-cd7-car-t-cells-t-cell-non-hodgkin-lymphoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →